Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/hypoimmune-and-gene-edited-stem-cells-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Stem Cell TechnologyHypoimmune and gene-edited stem cell patents: mapping the universal donor cell race
- One assignee, CRISPR Therapeutics, holds 140 of the 411 records in scope while fifth place sits at 20 and tenth place at 6 — a steep drop-off after the leader rather than an even spread.
- Filing fell 43% from 2021 to 2024 (74 to 42) the only three-year span in the trend that is complete enough to call a direction; 2025-2026 are still filling in under publication lag.
- G01N testing and C12Q enzyme/DNA measurement sit far below the core cluster at 26.0% and 6.6% of records respectively, versus 70%+ for the core editing and formulation classes.
411
Published Records
-43%
Filing Growth 2021→2024
US
Leading Jurisdiction
31
Active Filers Ranked
Filing growth compares 2021 (74 records) with 2024 (42) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
Hypoimmune and gene-edited stem cell patents cover engineered cells designed to evade immune rejection in a recipient who is not the original donor — universal donor cells built through HLA knockout, natural killer evasion, and inducible safety switches. This dataset spans 411 published records filed between 2015 and the 2026-07-31 cut-off, drawn from a search across hypoimmune and universal donor cell terminology paired with the specific editing and safety-testing techniques — HLA knockout, NK evasion, safety switches, off-target editing, clonality assessment and tumorigenicity testing — that distinguish a clinically credible construct from a research concept.
Because publication lags filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity; the 2024 figure is the last one solid enough to draw a conclusion from.
Filing activity and technology composition, 2017-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Numbers
Filing trend and technology composition
The trend line and the IPC breakdown below are drawn from the same 411 records that anchor every figure on this page.
A single peak year, then a documented pullback
Filings rose from 18 in 2017 to a peak of 88 in 2023, then declined to 42 by 2024 — a 43% fall from the 2021 level of 74. That is the last complete year in the series; 2025 and 2026 figures will continue to rise as publications catch up with filing dates, so they should not yet be read as a continued slide.
Editing and formulation dominate; testing and QC lag
C07K (peptides and proteins), C12N (genetic engineering) and A61K (medicinal preparations) each cover more than seven in ten of the 411 records, showing that most filings claim the edited cell construct itself. G01N (material analysis and testing) appears in 26.0% of records and C12Q (enzyme/DNA measurement) in just 6.6% — the assays that qualify a construct as safe for the clinic are claimed far less often than the construct itself.
Shares are the percentage of the 411 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Hypoimmune and Gene Edited Stem Cells with Eureka
This page is one run against one query. Ask Eureka your own question about hypoimmune and gene edited stem cells and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The most-cited filings in this space
Representative Filing
US20210069256A1 — Universal donor cells (CRISPR Therapeutics AG, filed 2021-03-11)
CRISPR THERAPEUTICS AG
Genetically modified cells compatible with multiple subjects — universal donor cells — carry at least one genetic modification near a gene encoding a survival factor, inserting a polynucleotide encoding a tolerogenic factor. The construct further modifies genes encoding MHC-I or MHC-II human leukocyte antigens, or a regulator of the MHC complex, to reduce immune recognition across unmatched recipients.Abstract text is truncated in the source record; full claim language should be reviewed before relying on scope.
Highest-cited records in the dataset
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2018058002A1 | TCRS specific for minor histocompatibility (h) antigen ha-1 and uses thereof | 91 |
| 2 | WO2020049535A1 | Universal donor cells | 43 |
| 3 | WO2021146627A1 | Safety switches for regulation of gene expression | 26 |
| 4 | US20200080107A1 | Universal donor cells | 26 |
| 5 | WO2022020319A2 | Binding proteins recognizing SARS-COV-2 antigens and uses thereof | 23 |
| 6 | WO2022036150A1 | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions | 22 |
| 7 | US10724052B2 | Universal donor cells | 22 |
| 8 | US20200080114A1 | Universal donor cells | 21 |
| 9 | US20210070835A1 | Universal donor cells | 19 |
| 10 | US10865424B2 | Universal donor cells | 19 |
Citation counts are measured within this searched corpus and favour older filings; treat them as a signal of influence on later work, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data means for a filing decision
Three patterns stand out once the ranking, the trend and the IPC composition are read together.
Concentration
140 vs 20
leader vs fifth place, in records
One filer, then a steep drop
CRISPR Therapeutics holds 140 of the 411 records in scope. Fifth place sits at 20 and tenth at 6 — a long tail of entrants each holding a handful of families rather than a second or third concentrated competitor.
31 ranked assignees in total
Momentum
-43%
2021 to 2024 filing change
A real pullback, not yet a trend past 2024
Filings dropped from 74 in 2021 to 42 in 2024, the last year complete enough to trust. Recent-year momentum by assignee shows the same pattern: several leading filers show 0 in the latest tracked year, though publication lag means this understates true 2025-2026 activity.
Peak year: 2023 at 88 filings
Technology gaps
6.6%
share of records in C12Q (enzyme/DNA measurement)
Safety and QC assays are thin relative to the construct claims
G01N testing (26.0%) and C12Q enzyme/DNA measurement (6.6%) trail C07K, C12N and A61K by a wide margin. Tumorigenicity testing and clonality assessment are named in the search scope but are comparatively under-claimed as their own subject matter.
Based on IPC subclass share of 411 records
Jurisdictions
US 71 · PCT 58
leading receiving offices
Filing strategy still centres on the US and PCT route
The United States (71) and WIPO/PCT (58) lead receiving offices, ahead of Australia (50), Europe (43), Israel (35) and Canada (24) — a filing footprint typical of a field still establishing composition-of-matter positions before broad regional build-out.
Six receiving offices tracked
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to hypoimmune and gene edited stem cells, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the field is still open
The ranking is dominated by one company, but the co-assignee pairs and the under-claimed IPC branches point to where new entrants are still finding room.
Leader
140 records
of 411 in scope
CRISPR Therapeutics
The clear leader in this ranking, with a filing footprint more than seven times the fifth-place holder. Recent-year momentum shows a decline of 64% year-on-year in the latest tracked period, consistent with the broader post-2021 pullback rather than a company-specific retreat.
Assignee of the representative filing US20210069256A1
Academic anchor
10 co-assignee pairs
strongest pairing 20 shared records
Dana-Farber and academic partners
The strongest co-assignee pairing in the dataset links Dana-Farber Cancer Institute with a corporate partner across 20 shared records, with a second pairing to Leiden University Medical Center at 10. Co-filing here signals joint IP ownership around specific antigen or editing targets rather than pure licensing.
Additional pairing at 7 shared records
Second tier
20 records
fifth-place holder
A long tail below the leader
Sana Biotechnology, academic medical centres and university systems each hold single-digit-to-low-double-digit record counts. Momentum data shows several of these at 0 filings in the latest tracked year, though this should be read against the 18-month publication lag rather than as a definitive exit.
Tenth place holds 6 records
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| CRISPR Therapeutics | 4 | -64% |
| CRISPR Therapeutics AG | 1 | 0% |
| Sana Biotechnology Inc | 0 | -100% |
| Dana-Farber Cancer Institute Inc | 0 | — |
| The Regents of the University of California | 0 | -100% |
| Fred Hutchinson Cancer Research Center | 0 | — |
| Fred Hutchinson Cancer Center | 0 | -100% |
| Academisch Ziekenhuis Leiden (LUMC) | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this next
The trend and ranking here answer who is filing and how densely; the next step is usually claim-level review against a specific construct or jurisdiction.
Check freedom-to-operate on a specific construct
Filing density in C07K and C12N means most core HLA-knockout and tolerogenic-factor constructs sit near existing claims. A claim-by-claim comparison against the leading filer's family is the practical next step before committing to a specific edit.
Run a claim comparison in EurekaTrack the under-claimed testing branches
Tumorigenicity testing and clonality assessment are named in this search scope but sit well below the core construct classes in filing share. Monitoring new filings in these branches over the next few publication cycles will show whether that gap is closing.
Set up a monitoring alert in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
CRISPR Therapeutics is the clear leader in this dataset, holding 140 of the 411 records in scope, well ahead of the fifth-ranked assignee at 20 records and the tenth at 6. Sana Biotechnology, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center and several university systems make up the rest of the ranked field of 31 companies. The gap between first and second place is wide enough that a freedom-to-operate review in this space should start with the leader's family before looking at anyone else.
Filings peaked at 88 in 2023 and fell to 42 by 2024, a 43% drop from the 2021 level of 74 — the last three-year span complete enough to draw a conclusion from. Figures for 2025 and 2026 are still filling in because publication typically lags filing by around 18 months, so it is too early to call this a sustained decline rather than a post-peak correction. Anyone using this trend for planning should treat 2024 as the most recent reliable data point.
Testing and quality-control methods trail the core construct claims by a wide margin: G01N material analysis and testing appears in 26.0% of the 411 records and C12Q enzyme/DNA measurement in just 6.6%, compared with over 70% for the core editing and formulation classes. Specific sub-areas worth checking include tumorigenicity testing protocols, clonality assessment methods, and off-target editing detection assays. These are named in the search scope itself, meaning they are technically relevant to the field but comparatively thin in claim coverage so far.
US20210069256A1, assigned to CRISPR Therapeutics AG and filed in March 2021, claims universal donor cells carrying a genetic modification near a gene encoding a survival factor, into which a polynucleotide encoding a tolerogenic factor is inserted. It further covers modification of genes encoding MHC-I or MHC-II human leukocyte antigens or their transcriptional regulators, to reduce immune recognition in unmatched recipients. Because the abstract text available here is truncated, the specific claim scope and any limiting language should be checked against the full granted claims before relying on this description for a design-around.
The United States (71 filings) and the WIPO/PCT route (58) are the most contested receiving offices, followed by Australia (50), Europe (43), Israel (35) and Canada (24). Combined with the fact that C07K, C12N and A61K each cover more than seven in ten of the 411 records, the densest claim space is squarely in US and PCT filings on the core edited-cell construct. Testing-method claims and filings in less-covered receiving offices represent comparatively more open ground, though that should be confirmed with a jurisdiction-specific search rather than assumed from this dataset alone.
Answers are grounded in the same dataset. Derived from a Patsnap search on Hypoimmune and Gene Edited Stem Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Hypoimmune and Gene Edited Stem Cells in depth with Eureka
Go past this page: query the whole hypoimmune and gene edited stem cells corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.